Treatment Watch

2591 eventsUpdated today

FDA drug approvals, PDUFA decisions, orphan designations, and breakthrough therapy designations for rare diseases — sourced daily from FDA.gov.

FDA data is sourced from FDA.gov and openFDA.
Report missing data
All eventsFDA approval (873)PDUFA date (0)Orphan designation (0)Breakthrough therapy (0)Complete response letter (0)Upcoming only·Year:All2015201420132012201120102009200820072006

33 events · 2006

Dec 20
2006
FDA approvalOrphan drug
Colazal (Balsalazide disodium)

Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.

Ulcerative colitis· Salix Pharmaceuticals, Inc.
Dec 19
2006
label expansion
DEPAKOTE SPRINKLES (DIVALPROEX SODIUM)FDA label ↗
· AbbVie Inc.· NDA019680
Dec 17
2006
label expansion
VALPROIC ACID (VALPROIC ACID)
Juvenile absence epilepsy· Bionpharma Inc.· ANDA073484
Dec 15
2006
FDA approvalOrphan drug
Cyanokit (Hydroxocobalamin)

Treatment on known or suspected cyanide poisoning

Cyanide poisoning· SERB, S.A.
Dec 15
2006
label expansion
VALPROIC ACID (VALPROIC ACID)
Juvenile absence epilepsy· Xttrium Laboratories Inc.· ANDA070868
Dec 5
2006
label expansion
GABAPENTIN (GABAPENTIN)
Post-herpetic neuralgia· Actavis Pharma, Inc.· ANDA075350
Dec 4
2006
label expansion
CARTIA XT (DILTIAZEM HYDROCHLORIDE)
· Actavis Pharma, Inc.· ANDA074752
Dec 1
2006
label expansion
VFEND (VORICONAZOLE)FDA label ↗
· Roerig· NDA021267
Nov 29
2006
label expansion
ZYPREXA INTRAMUSCULAR (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021253
Nov 29
2006
label expansion
ZYPREXA ZYDIS (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021086
Oct 19
2006
label expansion
TOPAMAX (TOPIRAMATE)FDA label ↗
Lennox-Gastaut syndrome· Janssen Pharmaceuticals, Inc.· NDA020844
Oct 19
2006
label expansion
TOPAMAX (TOPIRAMATE)FDA label ↗
Lennox-Gastaut syndrome· Janssen Pharmaceuticals, Inc.· NDA020505
Oct 13
2006
label expansion
DEPAKOTE SPRINKLES (DIVALPROEX SODIUM)FDA label ↗
· AbbVie Inc.· NDA019680
Oct 6
2006
FDA approvalOrphan drug
Zolinza (vorinostat)

Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.

T-cell non-Hodgkin lymphoma· Merck & Co., Inc.
Sep 7
2006
label expansion
CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)FDA label ↗
Isolated hyperchlorhidrosis· Janssen Pharmaceuticals, Inc.· NDA021121
Aug 25
2006
label expansion
ZYPREXA INTRAMUSCULAR (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021253
Aug 25
2006
label expansion
ZYPREXA ZYDIS (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021086
Jul 26
2006
FDA approvalOrphan drug
Normocarb HF (bicarbonate infusate)

Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children

Late-onset retinal degeneration· Dialysis Solutions, Inc.
Jul 25
2006
FDA approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM AND SULBACTAM SODIUM)
· Hospira, Inc· ANDA065310
Jun 21
2006
label expansion
DRONABINOL (DRONABINOL)FDA label ↗
Robinow-like syndrome· Ascend Laboratories, LLC· NDA018651
May 19
2006
label expansion
VFEND (VORICONAZOLE)FDA label ↗
· Roerig· NDA021267
May 2
2006
FDA approvalOrphan drug
Decitabine (DECITABINE)

for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups

Myelodysplastic syndrome· BluePoint Laboratories· ANDA212826
Apr 28
2006
FDA approvalOrphan drug
Myozyme (Recombinant human acid alpha-glucosidase; alglucosidase alfa)

Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy.

Glycogen storage disease due to acid maltase deficiency· Genzyme Corporation
Apr 13
2006
FDA approvalOrphan drug
NeoProfen (Ibuprofen lysine)

For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective

Premature closure of the arterial duct· Lundbeck, Inc.
Mar 10
2006
label expansion
VFEND (VORICONAZOLE)FDA label ↗
· Roerig· NDA021267
Mar 6
2006
label expansion
SANDIMMUNE (CYCLOSPORINE)FDA label ↗
Vernal keratoconjunctivitis· Novartis Pharmaceuticals Corporation· NDA050625
Mar 6
2006
label expansion
ACYCLOVIR (ACYCLOVIR)
Infective dermatitis associated with HTLV-1· Apotex Corp.· ANDA075677
Mar 1
2006
FDA approvalOrphan drug
Erbitux (cetuximab)

For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed

Squamous cell carcinoma of liver and intrahepatic biliary tract· ImClone Systems Incorporated
Feb 23
2006
label expansion
ZYPREXA INTRAMUSCULAR (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021253
Feb 23
2006
label expansion
ZYPREXA ZYDIS (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021086
Feb 16
2006
label expansion
ZYPREXA INTRAMUSCULAR (OLANZAPINE)FDA label ↗
· Eli Lilly and Company· NDA021253
Feb 16
2006
label expansion
ZYPREXA ZYDIS (OLANZAPINE)
· Eli Lilly and Company· NDA021086
Jan 11
2006
label expansion
DEPAKOTE SPRINKLES (DIVALPROEX SODIUM)FDA label ↗
· AbbVie Inc.· NDA019680

Not medical advice — always consult your healthcare provider before making treatment decisions.

Data sourced from FDA.gov and openFDA, updated daily. Dates are subject to change. Always verify with FDA.gov for official decisions.